Cancer Radiotherapy: General Considerations and Human Radiobiology
Advancements in oncologic therapies have led to increasing numbers of long-term cancer survivors and thus more patients for whom radiation therapy is indicated as part of their comprehensive treatment plan. Here we provide an overview of the biologic mech
- PDF / 12,091,463 Bytes
- 271 Pages / 439.43 x 683.15 pts Page_size
- 72 Downloads / 201 Views
123
Locoregional Radionuclide Cancer Therapy
Franklin C. L. Wong Editor
Locoregional Radionuclide Cancer Therapy Clinical and Scientific Aspects
Editor Franklin C. L. Wong Department of Nuclear Medicine University of Texas, M. D. Anderson Cancer Center Houston, TX USA
ISBN 978-3-030-56266-3 ISBN 978-3-030-56267-0 (eBook) https://doi.org/10.1007/978-3-030-56267-0 © Springer Nature Switzerland AG 2021 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
Radionuclide therapy by systemic administration is becoming mainstay of cancer therapy. It has developed from radio-iodide ablation to radionuclide palliative treatment of intractable cancer bone pain (Sr-89, Sm-153 EDTMP and Ra-223) and further to radioimmunotherapy (Lu-177 PSMA and other ligands) as well as treatment of osseous metastasis (Ra-223). Locoregional radionuclide therapy (LRCT) has great potential of harnessing pharmacokinetic advantages to expand therapeutic windows but is still in developing stages. Although LRCT shares locoregional characteristics of the widely accepted cancer therapy external beam radiotherapy, wide adoption of LRCT is limited by lack of understanding of its effects and radiation dosimetry to the target organs and to the rest of the organism. Recent advances in instrumentation, imaging algorithm, and radiation dosimetry modeling have allowed accurate imaging of minute amounts of radioactivity in small volumes. Therefore, this is a prudent time to revisit the theoretical bases and practical issues of LRCT in the application to human cancer. The scope of human cancer, the current therapies, and locoregional radiotherapy of cancer are reviewed in the first three chapters. The current practices of rad
Data Loading...
